论文部分内容阅读
欧洲委员会宣布批准temozolomide(Temodal)在欧洲市场出售,用于治疗复发性多形性恶性胶质瘤。伦敦癌研究运动的发言人Gordon MoVie指出,temozolomide是过去20年中在脑瘤治疗方面最重要的进展。但是他对该药是否能在英国广泛应用表示怀疑。
The European Commission announced the approval of temozolomide (Temodal) for sale in the European market for the treatment of recurrent glioblastoma multiforme. Gordon MoVie, spokesman for the London Cancer Research Campaign, said temozolomide is the most significant advance in brain tumor treatment over the past two decades. But he is skeptical about whether the drug will be widely available in the UK.